
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at whether nivolumab can improve treatment before a stem cell transplant for people with Hodgkin lymphoma.
This is the first time people with Hodgkin lymphoma are having nivolumab before a stem cell transplant. So there might be some side effects we don’t know about yet. The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Nivolumab can affect the immune system. It may cause inflammation in different parts of the body which can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening.
If you have any of these side effects, you should tell the doctor or nurse as soon as possible that you are on or have been on an immunotherapy.
Some common side effects of nivolumab include:
Other ‘immune’ symptoms can range from mild to severe and include:
The trial team will go through all the possible side effects of treatment. They’ll monitor you for any of the above symptoms and treat them straight away.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Graham Collins
Cancer Research UK & UCL Cancer Trials Centre
Bristol-Myers Squibb
University College London
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.